Today, we're digging into a topic that's getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is Freeze Variability, Not Progress, How to Strengthen Your Cell Therapy Supply Chain from the Start, and we're going to challenge a few long-held beliefs about how starting material should be handled. My guest today is Dominic Clarke, Vice President of Technical Operations for IntegriCell at Cryoport Systems. Dominic has spent years in the trenches building and scaling cell therapy processes from early development through commercialization. So, he's seen where things break and what actually works. I hope you enjoy my conversation with Dominic Clark.01:07    Meet Dominic Clarke and Cryoport Systems06:24   Fresh cells versus frozen cells08:21    Why teams switch to cryopreservation late12:37    The challenge of variability16:47    IntegriCell when you already have a process in place22:17    An argument for cryopreservation based on data25:56   The future of IntegriCell and Cryoport SystemsThis episode is brought to you with the support of Cryoport Systems.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: IntegriCell® CryopreservationCryoport Systems on the state of the ATMP market and the importance of supply chain resilienceCracking the code: Delivering biotherapeutics successfully across EMEA